Esophageal adenocarcinoma (OE19, FLO-1), colon (HCT116) and breast (MCF7) cancer cell lines were treated with RAD51 inhibitor (RI-1), camptothecin (CPT) or combination of both for 48 h and cell viability assessed as described in Methods. This evidence concerns the gene RAD51 and esophageal adenocarcinoma.